Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase
作者:Aimin Song、Xiaobing Wang、Jinhua Zhang、Jan Mařı́k、Carlito B. Lebrilla、Kit S. Lam
DOI:10.1016/j.bmcl.2003.09.067
日期:2004.1
polyoxyethylene-based amino acid type linkers were designed and synthesized for peptide derivatization in solid phase. Three of them were obtained in a crystalline form. The crystallized linkers can be stored at 4 degrees C for 2 years without significant decomposition. Protocols for biotinylation and fluorescent labeling of peptides in solid phase were developed. The linkers also provide good ionization ability
Alkylation of Staurosporine to Derive a Kinase Probe for Fluorescence Applications
作者:Alexander J. M. Disney、Barrie Kellam、Lodewijk V. Dekker
DOI:10.1002/cmdc.201500589
日期:2016.5.6
The natural product staurosporine is a high-affinity inhibitor of nearly all mammalian protein kinases. The labelling of staurosporine has proven effective as a means of generating protein kinase research tools. Most tools have been generated by acylation of the 4'-methylamine of the sugar moiety of staurosporine. Herein we describe the alkylation of this group as a first step to generate a fluorescently
Facile solid phase synthesis of 1,2-disubstituted-6-nitro-1,4-dihydroquinazolines using a tetrafunctional scaffold
作者:Xiaobing Wang、Aimin Song、Seth Dixon、Mark J. Kurth、Kit S. Lam
DOI:10.1016/j.tetlet.2004.11.095
日期:2005.1
Solidphasesynthesis of 1, 2-disubstituted-6-nitro-1,4-dihydroquinazolines is described. The new tetrafunctional scaffold N-Alloc-3-amino-3-(2-fluoro-5-nitrophenyl)propionic acid was prepared by nitration of 3-amino-3-(2-fluorophenyl)propionic acid. The scaffold was anchored to Rink resin via its carboxylic group and treated with primary amines to displace the arylfluorine followed by cyclization
[EN] PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS<br/>[FR] PEPTIDES POUR L'ACTIVATION DE LA SIGNALISATION CELLULAIRE DANS DES CELLULES OSTÉOPROGÉNITRICES
申请人:UNIV CALIFORNIA
公开号:WO2020018941A1
公开(公告)日:2020-01-23
The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.
[EN] LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT<br/>[FR] CONJUGUÉS LLP2A-BISPHOSPHONATE POUR LE TRAITEMENT DE L'OSTÉOPOROSE
申请人:UNIV CALIFORNIA
公开号:WO2013032527A1
公开(公告)日:2013-03-07
The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.